Oramed Pharmaceuticals (ORMP) Shares Outstanding (Diluted Average) (2021 - 2026)

Oramed Pharmaceuticals has reported Shares Outstanding (Diluted Average) for 6 years, with the latest figure at $42.0 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 1.8% year-over-year to $42.0 million; the trailing twelve-month figure through Mar 2026 stood at $42.0 million (up 1.8% YoY), and the FY2025 full-year result was $42.4 million, up 3.84% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $42.0 million, down from $42.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $43.0 million in Q3 2025, with the low at $38.7 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $40.8 million across 5 years, with a median of $40.9 million in 2024.
• The largest YoY upside for Shares Outstanding (Diluted Average) was 5.11% in 2025 against a maximum downside of 0.81% in 2025.
• Oramed Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $39.0 million in 2022, then climbed by 4.02% to $40.6 million in 2023, then gained by 0.7% to $40.9 million in 2024, then increased by 3.84% to $42.4 million in 2025, then decreased by 1.06% to $42.0 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $42.0 million (Q1 2026), $42.4 million (Q4 2025), and $43.0 million (Q3 2025), per Business Quant data.